**Abstract**

Valproic acid (VPA) is widely used as an anticonvulsant and mood-stabilizing drug. However, since the prenatal exposure of VPA shows increased incidence of autism spectrum disorder (ASD), the administration of VPA in the pregnancy period is forbidden. In contrast, rodent pups exposed *in utero* to VPA have been used as an animal model of ASD. Recently, decreased or increased mammalian target of rapamycin (mTOR) signaling pathway was shown in VPA-exposed rodents (Nicolini et al., 2015, Qin et al., 2015). The mTOR signaling pathway regulates neuronal cell proliferation, migration and maturation, including synaptogenesis, and overactivation of the mTOR signaling has been implicated in the pathogenesis of particular forms of syndromic ASDs, such as tuberous sclerosis complex (TSC), neurofibromatosis 1, and fragile X syndrome. Treatment with rapamycin, mTOR complex 1 inhibitors, in a mouse model of TSC improved abnormal behaviors, including cognition and sociability. In this study, we investigated the effect of rapamycin on social deficits of ASD model mice exposed *in utero* to VPA. We subcutaneously injected VPA at a dose of 600 mg/kg body weight (B.W.) into pregnant mice on gestational day 12.5, and the pups were injected intraperitoneally with rapamycin (10 mg/kg B.W.) or an equal volume of vehicle once daily for 2 consecutive days. Social interaction test was performed at 24 h after the last administration of rapamycin in 5--6 week-old mice (adolescence) or 10--11 week-old mice (young adult). The administration of rapamycin showed improvement in the social deficits in both adolescence and young adult mice compared with the saline injected control mice. These results suggest that rapamycin has potential to provide an effective treatment for adolescent and young adult patients with not only particular syndromic ASD but also non-syndromic ASD.
